Insider Buying Surge: Recent buzz on social media has centered around significant insider buying at Cabaletta Bio, with multiple top executives reportedly purchasing shares. This activity, highlighted by various users, has sparked a notable uptick in the stock price, with some noting intraday gains of nearly 30%. The sentiment around these purchases is largely positive, as many see it as a strong vote of confidence from leadership.
Clinical Progress Buzz: Discussions also focus on the company’s updates regarding its RESET program for autoimmune diseases, with users pointing to progress in manufacturing and strategic priorities for 2026. Posts suggest excitement over the potential of their CAR-T therapies, with some anticipating key data releases in the coming months. The tone here remains optimistic, with many intrigued by the long-term prospects of these treatments.
Note: This discussion summary was generated from an AI condensation of post data.
Cabaletta Bio Insider Trading Activity
Cabaletta Bio insiders have traded $CABA stock on the open market 8 times in the past 6 months. Of those trades, 8 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CABA stock by insiders over the last 6 months:
- STEVEN NICHTBERGER (President & CEO) purchased 45,000 shares for an estimated $100,777
- SHAWN TOMASELLO purchased 22,725 shares for an estimated $50,322
- STEVE GAVEL (Chief Commercial Officer) purchased 22,170 shares for an estimated $50,215
- MARK SIMON purchased 11,061 shares for an estimated $25,261
- GWENDOLYN BINDER (President, Science & Tech.) purchased 11,312 shares for an estimated $24,763
- DAVID J. CHANG (Chief Medical Officer) purchased 8,800 shares for an estimated $19,887
- MICHAEL GERARD (General Counsel) purchased 6,600 shares for an estimated $14,979
- CATHERINE BOLLARD purchased 4,405 shares for an estimated $9,982
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Cabaletta Bio Hedge Fund Activity
We have seen 36 institutional investors add shares of Cabaletta Bio stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. removed 3,500,000 shares (-72.9%) from their portfolio in Q3 2025, for an estimated $8,189,999
- JENNISON ASSOCIATES LLC added 2,477,370 shares (+41.2%) to their portfolio in Q3 2025, for an estimated $5,797,045
- JEFFERIES FINANCIAL GROUP INC. removed 1,949,708 shares (-97.6%) from their portfolio in Q3 2025, for an estimated $4,562,316
- ANSON FUNDS MANAGEMENT LP removed 1,822,830 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $4,265,422
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,568,701 shares (+23.1%) to their portfolio in Q3 2025, for an estimated $3,670,760
- RENAISSANCE TECHNOLOGIES LLC added 1,213,323 shares (+962.2%) to their portfolio in Q3 2025, for an estimated $2,839,175
- BURKEHILL GLOBAL MANAGEMENT, LP removed 1,200,000 shares (-63.2%) from their portfolio in Q3 2025, for an estimated $2,808,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Cabaletta Bio Analyst Ratings
Wall Street analysts have issued reports on $CABA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/10/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/05/2025
To track analyst ratings and price targets for Cabaletta Bio, check out Quiver Quantitative's $CABA forecast page.
Cabaletta Bio Price Targets
Multiple analysts have issued price targets for $CABA recently. We have seen 3 analysts offer price targets for $CABA in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- Josh Schimmer from Cantor Fitzgerald set a target price of $30.0 on 10/31/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $16.0 on 10/10/2025
- Derek Archila from Wells Fargo set a target price of $2.0 on 08/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
